๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
The Effects of Ferric Derisomaltose on Postoperative Anemia in Spinal Deformity Surgery
NCT05714007Perioperative Anemia, Surgery, Spinal Deformity, Adult
DrugFerric Derisomaltose
Peking Union Medical College Hospital
Phase 4
120
Beijing
2023-08-31
Not yet open
Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
NCT05988177Carbapenem Resistant Bacterial Infection, Hemophagocytic Lymphohistiocytoses
Beijing Friendship Hospital
Not applicable
20
Beijing
2023-08-30
Recruiting
Digital Cognitive Behavioral Therapy for Insomnia for Chronic Insomnia in Breast Cancer Survivors
NCT05813392Chronic Insomnia
Peking University First Hospital
Not applicable
264
Beijing
2023-08-29
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Nanchang, Shanghai
2023-08-28
Recruiting
Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis
NCT05885932Ischemic Stroke, Vertebral Artery Stenosis
DrugTicagrelor
Xuanwu Hospital, Beijing
Not applicable
472
Beijing
2023-08-25
Recruiting
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
NCT05954910Diffuse Large B-Cell Lymphoma
DrugPolatuzumab Vedotin
Hoffmann-La Roche
Observational
1,000
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Haikou, Hohhot
2023-08-25
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
DrugTezepelumab
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Recruiting
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964Atopic Dermatitis
DrugPF-07275315
Pfizer
Phase 2
340
Beijing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Changsha, Wuhan, Zhenjiang
2023-08-22
Active, closed
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNฮฑ Combination Therapy in Chronic HBV Patients
NCT05970289Chronic Hepatitis B Virus Infection
Brii Biosciences Limited
Phase 2
86
Beijing, Chongqing, Guangzhou, Hong Kong, Changchun, Shanghai, Kaohsiung, Taipei
2023-08-22
Recruiting
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
NCT06975618PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM)
DrugCYH33
Haihe Biopharma Co., Ltd.
Phase 1/2
141
Beijing, Fuzhou, Guangzhou, Zhengzhou, Changsha, Shanghai, Chengdu
2023-08-22
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
NCT06355934ATTR Amyloidosis
AstraZeneca
Observational
52,121
Beijing, Changsha, Chengdu, Guangzhou, Wuhan
2023-08-21
Active, closed
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
NCT06174402Primary Biliary Cholangitis
Han Ying
Phase 2/3
184
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Yanโ€™an, Kunming, Beijing
2023-08-21
Recruiting
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832Myasthenia Gravis
Peking Union Medical College Hospital
Observational
202
Beijing
2023-08-20
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Beijing, Jinan, Neijiang, Shanghai
2023-08-18
Recruiting
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116Advanced Solid Tumors
DrugsBNT324·Abiraterone·Itraconazole·Enzalutamide
DualityBio Inc.
Phase 1/2
862
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin
2023-08-17
Recruiting
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NCT05948813NSCLC, EGFR Activating Mutation, Brain Metastases
DrugOsimertinib
TYK Medicines, Inc
Phase 2
420
Beijing
2023-08-17
Active, closed
Study of XGEVAยฎ (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
NCT04586660Giant Cell Tumor of Bone
Amgen
Phase 4
36
Beijing, Fuzhou, Guangzhou, Harbin, Xi'an, Hangzhou
2023-08-17
Recruiting
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
NCT05866692Solid Tumor, Adult
TYK Medicines, Inc
Phase 1
156
Beijing, Jinan
2023-08-17
Active, closed
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
NCT06577792Non Small Cell Lung Cancer
Sun Yat-sen University
Not applicable
620
Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing
2023-08-16
Active, closed
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
NCT05885555Primary Immune Thrombocytopenia (ITP)
DrugIanalumab
Novartis Pharmaceuticals
Phase 2
41
Wuhan, Beijing, Jinan
2023-08-16
Recruiting
A Study of BA1202 in Patients With Advanced Solid Tumors
NCT05909241Advanced Solid Tumor
Shandong Boan Biotechnology Co., Ltd
Phase 1
78
Beijing
2023-08-16
Recruiting
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
NCT05983237Melanoma
Jun Guo
Phase 1/2
50
Beijing
2023-08-15
Recruiting
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
NCT06145308Salivary Gland Carcinoma, Precision Therapy
DrugsIparomlimab·Pertuzumab/Trastuzumab·TROP2 ADC·Bicalutamide
Peking Union Medical College
Phase 2
39
Beijing
2023-08-15
Not yet open
KN026 Plus Chemotherapy ยฑ KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
NCT05985707HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer
Peking University Cancer Hospital & Institute
Phase 2
80
Beijing
2023-08-15
Recruiting
Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
NCT05905172Liver Fibrosis
DrugHydronidone
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3
248
Beijing, Shanghai, Bengbu, Changsha, Chongqing, Guizhou, Hangzhou, Henan
2023-08-12
Recruiting
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
NCT06015048HER2-expressing Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
364
Hefei, Beijing, Chongqing, Nanning, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-08-11
Active, closed
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
NCT05909397Breast Cancer
DrugsVepdegestrant·Letrozole
Pfizer
Phase 3
59
Beijing, Guangzhou, Wuhan, Xi'an
2023-08-09
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Beijing, Cangzhou Shi, Shijiazhuang, Wuxi, Changzhou, Chengdu, Guangzhou, Hangzhou
2023-08-08
Active, closed
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
NCT05896124Primary Biliary Cholangitis (PBC)
DrugCS0159
Cascade Pharmaceuticals, Inc
Phase 2
75
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Zhenjiang, Changchun
2023-08-07
Active, closed
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
NCT05896137Primary Sclerosing Cholangitis
DrugCS0159
Cascade Pharmaceuticals, Inc
Phase 2
50
Hefei, Beijing, Wuhan, Changsha, Changchun, Jinan, Shanghai, Hangzhou
2023-08-07
Recruiting
A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
NCT05970016Patients with Advanced Solid Tumors
Beijing Tide Pharmaceutical Co., Ltd
Phase 1/2
56
Beijing
2023-08-07
Recruiting
The Beijing Longitudinal Disability Survey in Community Elderly
NCT06863727Ageing, Disability, Cognitive Impairment, Frailty
Xuanwu Hospital, Beijing
Observational
1,962
Beijing
2023-08-07
Recruiting
Clinical Characteristics and Molecular Mechanism of Patients With Obstructive Sleep Apnea
NCT07277608Obstructive Sleep Apnea
Capital Medical University
Observational
500
Beijing
2023-08-07
Active, closed
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
NCT05980481Gastric Cancer
DrugsDisitamab Vedotin·Trastuzumab·Oxaliplatin·Capecitabine
RemeGen Co., Ltd.
Phase 2/3
201
Beijing
2023-08-04
Recruiting
Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD
NCT05921305Acute Graft Versus Host Disease
Peking University People's Hospital
Phase 3
218
Beijing, Guangzhou
2023-08-03
Recruiting
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
NCT05698147Central Nervous System Lymphoma
DrugsMethotrexate·Selinexor·Rituximab
Tong Chen, MD
Phase 1/2
30
Hefei, Beijing, Fuzhou, Zhengzhou, Shanghai
2023-08-03
Recruiting
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
NCT05867420Advanced Solid Tumors
DrugsFruquintinib·Bevacizumab·Paclitaxel
AskGene Pharma, Inc.
Phase 1/2
594
Beijing, Shanghai
2023-08-02
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
Recruiting
The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg
NCT06037473Growth Hormone Treatment, Growth Disorders
Beijing Children's Hospital
Observational
2,600
Beijing
2023-08-01
By invitation
Osteo Match Cages Versus PEEK Cages in Osteoporotic Patients
NCT05981222Osteoporosis, Degenerative Lumbar Disease, Degeneration Spine
Peking University Third Hospital
Observational
1,500
Beijing
2023-08-01
Active, closed
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
NCT05587374Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
DrugsCadonilimab·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Recruiting
Study on Therapeutic Mechanism of Natural Psychotherapy for Neurosis
NCT06443125Obsessive-Compulsive Disorder
Xiang Yang Zhang
Not applicable
50
Hefei, Beijing
2023-08-01
Recruiting
Real-world of AI in Diagnosing Retinal Diseases
NCT05981950Artificial Intelligence, Retinal Diseases
Beijing Tongren Hospital
Observational
100,000
Beijing
2023-08-01
Active, closed
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients
NCT05901987SMA II
GeneCradle Inc
Phase 1/2
33
Beijing, Chengdu, Chongqing, Wuhan
2023-08-01
Active, closed
A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
NCT06044350Optic Neuromyelitis Spectrum Disease
Bio-Thera Solutions
Phase 2
162
Baotou, Beijing, Changsha, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou
2023-08-01
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
DrugsCapeox·Dostarlimab·Folfox
GlaxoSmithKline
Phase 3
892
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2023-08-01
Recruiting
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
NCT06135922EBV-associated Hemophagocytic Lymphohistiocytosis, EBV Infection
Chinese PLA General Hospital
Phase 1
9
Beijing
2023-08-01
Recruiting
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT06084819Relapsed/Refractory Acute Myeloid Leukemia
DrugsAclacinomycin·Azacytidine·Granulocyte Colony-Stimulating Factor·Chidamide
Chinese PLA General Hospital
Phase 2
200
Beijing
2023-08-01
Recruiting
Safety and Effectiveness of TaurusTrioโ„ข Heart Valve System in Patients With Severe Aortic Regurgitation (AR)
NCT06101888Aortic Regurgitation
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
116
Beijing, Fuzhou, Xiamen, Guangzhou, Guangdong, Haerbin, Wuhan, Changsha
2023-08-01
Recruiting
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
NCT06119256EBV Infection After Allogenic HSCT
Chinese PLA General Hospital
Phase 1
12
Beijing
2023-08-01
Active, closed
Young Patients With Early Breast Cancer
NCT06027541Breast Cancer Female
Peking Union Medical College Hospital
Observational
1,000
Beijing
2023-08-01
Recruiting
Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT05994365Thyroid Neoplasms
DrugAnlotinib hydrochloride
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Observational
380
Beijing, Tianjin
2023-08
Active, closed
The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens
NCT05886348Myopia
HOYA Lens Thailand LTD.
Not applicable
249
Beijing, Guangzhou, Shanghai, Shengyang, Tianjin
2023-07-31
Recruiting
Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy
NCT05973097Oral Lichen Planus
Peking University Third Hospital
Not applicable
156
Beijing
2023-07-30
Not yet open
VitaFlowยฎ Transcatheter Aortic Valve Replacement System Pre-market Trial Long Term Follow Up ๏ผˆVITAL๏ผ‰
NCT05977257Aortic Valve Disease, Aortic Valve Stenosis
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Observational
89
Beijing, Chengdu, Hangzhou, Shanghai
2023-07-30
Active, closed
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593Geographic Atrophy
DrugTinlarebant
Belite Bio, Inc
Phase 3
429
Beijing, Chengdu, Guandong, Zhejiang
2023-07-27
Recruiting
A Study of EOC237 in Patients With Advanced Solid Tumor
NCT05895825Advanced Solid Tumor
Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Phase 1
48
Beijing
2023-07-26
Recruiting
Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD
NCT06243640Generalized Anxiety Disorder
DrugsBuagafuran mimic·Buagafuran
Beijing Union Pharmaceutical Factory Ltd
Phase 3
504
Beijing
2023-07-25
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
DrugUpadacitinib
AbbVie
Phase 3
1,014
Bengbu, Beijing, Xiamen, Guangzhou, Shantou, Nanning, Luoyang, Wuhan
2023-07-25
Recruiting
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers
NCT07392411Parkinson's Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy, Healthy Control
Beijing Tiantan Hospital
Observational
720
Beijing
2023-07-25
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
DrugsINCA33890·ADG126·Folfiri·Folfox
Incyte Corporation
Phase 1
570
Beijing, Hangzhou
2023-07-24
Recruiting
Phase โ…ข Clinical Trial of Buagafuran Capsules in the Treatment of GAD
NCT06243614Generalized Anxiety Disorder
DrugsBuagafuran mimic·Buagafuran
Beijing Union Pharmaceutical Factory Ltd
Phase 3
410
Beijing
2023-07-24
Recruiting
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
NCT05838066First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.
Phase 3
880
Beijing
2023-07-23
Recruiting
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
NCT05983107HR+/HER2- Advanced Breast Cancer, Targeted Therapy
DrugsEverolimus·Chidamide
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
102
Beijing
2023-07-20
Recruiting
Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract
NCT06430372Gastrointestinal Carcinoma, Dysplasia, Gastrointestinal Polyp
Institute of Automation, Chinese Academy of Sciences
Phase 1
30
Beijing
2023-07-20
Recruiting
Registry of X-linked Adrenoleukodystrophy
NCT05939232X-linked Adrenoleukodystrophy
Beijing Tiantan Hospital
Observational
200
Beijing
2023-07-20
Recruiting
Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
NCT06126510Sarcoma
CNBG-Virogin Biotech (Shanghai) Ltd.
Phase 2
40
Beijing
2023-07-18
Recruiting
Software Refraction With Mobilerone Versus Retinoscopy
NCT06059521Myopia, Myopia, Moderate, Astigmatism
Beijing Airdoc Technology Co., Ltd.
Not applicable
120
Beijing
2023-07-15
Recruiting
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
NCT05948033Lymphoma
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2023-07-15
Active, closed
The Beijing Adult Dry Eye Cohort Study
NCT06621446Dry Eye
Beijing Tongren Hospital
Observational
1,200
Beijing
2023-07-15
Recruiting
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors
NCT05947487Solid Tumor, Adult
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2023-07-15
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Nanchang
2023-07-11
Recruiting
Surgical Treatment of Irreducible Atlantoaxial Dislocation
NCT05847270Irreducible Atlantoaxial Dislocation
Peking University Third Hospital
Not applicable
70
Beijing
2023-07-11
Recruiting
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
NCT05911217Pancreatic Cancer
DrugCT041 autologous CAR T-cell
CARsgen Therapeutics Co., Ltd.
Phase 1
20
Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou
2023-07-11
Active, closed
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451Chronic Spontaneous Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
100
Guangzhou, Chengdu, Beijing
2023-07-11
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
AstraZeneca
Phase 1/2
280
Beijing, Shandong
2023-07-11
Recruiting
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
NCT05886920Advanced Solid Tumors With MAPK Pathway Mutations
DrugD3S-001
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
67
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu, Hangzhou
2023-07-10
Recruiting
Effects of Preoperative Rehabilitation on Tendon Healing, Bone Mineral Density, and Cartilage After ACLR and Patellar Dislocation
NCT05924178Anterior Cruciate Ligament Rupture
Peking University Third Hospital
Not applicable
60
Beijing
2023-07-10
Active, closed
Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).
NCT06175351Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Drug9MW1911
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
80
Baotou, Beijing, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou, Hengyang
2023-07-06
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
383
Hefei, Beijing, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan
2023-07-06
Recruiting
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
NCT05631886Solid Tumor, Adult, Lymphoma, EphA2 Overexpression, TP53 R273H
DrugsAbraxane·Cyclophosphamide
Chinese PLA General Hospital
Phase 1
10
Beijing
2023-07-04
Recruiting
Interactions Between Environmental Exposures and Gut Microbiota in Early Life
NCT06479928Infant Development
Peking University People's Hospital
Observational
756
Beijing
2023-07-01
Recruiting
Effects of Lactulose on Gut Microbiota and Metabolism in Diabetic Constipated Patients
NCT07065942Diabetes Mellitus, Constipation - Functional
Peking Union Medical College Hospital
Not applicable
60
Beijing
2023-07-01
Not yet open
The China CardioMyopathy Registry Study
NCT05871632Cardiomyopathies
China National Center for Cardiovascular Diseases
Observational
5,000
Beijing
2023-07-01
Recruiting
Study on the Health Economic Burden of Alzheimer's Disease in China
NCT05995418Alzheimer Disease
Xuanwu Hospital, Beijing
Observational
9,510
Beijing
2023-07-01
Recruiting
A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.
NCT05984537Coronary Microvascular Dysfunction
Peking University First Hospital
Phase 4
70
Beijing
2023-07-01
Recruiting
Short-term Cervical Spinal Cord Stimulation in Patients With Disorders of Consciousness After Intracerebral Hemorrhage
NCT05922644Coma, Stroke
Beijing Tiantan Hospital
Not applicable
344
Beijing
2023-07-01
Active, closed
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
NCT05814354Breast Cancer
DrugTrastuzumab Rezetecan
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
551
Beijing
2023-06-30
Recruiting
Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
NCT05962840ANCA Associated Vasculitis
DrugTelitacicept
Chinese SLE Treatment And Research Group
Phase 4
40
Beijing
2023-06-29
Active, closed
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Non Small Cell Lung Cancer
DrugsGotistobart·Paclitaxel
OncoC4, Inc.
Phase 3
630
Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou
2023-06-28
Active, closed
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769Chronic Obstructive Pulmonary Disease
DrugAstegolimab
Hoffmann-La Roche
Phase 3
2,000
Hefei, Beijing, Zunyi, Wuhan, Xuzhou, Pingxiang, Shanghai, Zigong
2023-06-28
Recruiting
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
NCT05806099Non-Hodgkin's Lymphoma
Beijing Mabworks Biotech Co., Ltd.
Phase 1/2
132
Beijing
2023-06-28
Active, closed
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
DrugsIrinotecan·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
123
Beijing, Guangzhou
2023-06-27
Active, closed
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
NCT06009861Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
DrugsAlbumin-Bound Paclitaxel·Cisplatin·Tislelizumab
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Active, closed
Clinical Efficacy of Early Left Bundle Branch Pacing for Cardiac Resynchronization Therapy
NCT06126081Heart Failure, Left Bundle Branch Pacing
DrugGDMT
Fu Wai Hospital, Beijing, China
Not applicable
36
Beijing, Nanjing
2023-06-26
Recruiting
Sirolimus in the Treatment of Refractory/Relapsed wAIHA
NCT05925023Warm Autoimmune Hemolytic Anemia
DrugPaclitaxel
Peking Union Medical College Hospital
Not applicable
22
Beijing
2023-06-24
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Recruiting
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
NCT07102004Advanced/Metastatic Solid Tumors
DrugMHB088C
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
515
Beijing
2023-06-20
Recruiting
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332Breast Cancer, Triple Negative Breast Cancer
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Recruiting
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
NCT07394374Solid Tumors Harboring NTRK Fusion, NTRK, NTRK Gene Fusion, NTRK Fusion Positive
Cullgen (Shanghai),Inc
Phase 1/2
42
Beijing, Chengdu, Guangzhou, Hangzhou, Taiyuan
2023-06-20
Rows per page Showing 4101–4200 of 5484
Previous 40 41 42 43 44 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=42

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.